The Chinese Market for Cancer Intervention

The Chinese Market for Cancer Intervention

  • June 2017 •
  • 130 pages •
  • Report ID: 4977682
• The Chinese cancer intervention market reached nearly $41.1 billion in 2016. This market should reach $46.7 billion in 2017 and $89.3 billion by 2022, at a compound annual growth rate (CAGR) of 13.8% through 2022.
• Cancer treatment services as a segment should reach nearly $43.9 billion in 2017 and $83.6 billion by 2022, at a CAGR of 13.8% through 2022.
• Diagnosis and detection services as a segment should reach nearly $2.9 billion in 2017 and $5.8 billion by 2022, at a CAGR of 15.0% through 2022.

Chapter 1: Introduction


Study Goals and Objectives
The Chinese cancer intervention market is big, fast-growing, and dominated by drug and equipment suppliers from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions and which are looking for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehensive understanding of the recent advances and trends in the cancer intervention industry and market in China. Toward this end, this report will cover the market for products for different types of cancer to 2022. The report provides a comprehensive discussion of cancer intervention applications, industry structure, marketing and distribution, partnerships, and companies. The report is designed to aid companies in their strategic planning efforts for accessing cancer intervention industry opportunities in the Chinese market.


Reasons for Doing This Study
This study will help pharmaceutical companies, medical equipment suppliers, medical institutions, and drug wholesalers and distributors gain an in-depth understanding on the Chinese cancer intervention market.


Scope of Report
The scope of the report includes cancer intervention applications, industries, markets, and companies in China. The markets for cancer intervention are given for the years 2016, 2017 and 2022. The Chinese cancer intervention market includes two major segments: cancer treatment and cancer diagnosis and detection. Each major segment will be further divided and discussed by technology, drug type, end user, etc. In this report, China is referred to as Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities), and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai and others.


Information Sources
Information sources for this report include experts, executives, professors, and officials in the Chinese cancer intervention industry. They are from pharmaceutical companies, associations and governmental departments. Information sources for the study also include online research, patent literature, technical journals, trade magazines, governmental data, public speeches, and conference papers.


Methodology
Both primary and secondary research methodologies were used in preparing this study. Estimates of current market demand are made for 2016 and are projected for the next five years from 2017 through 2022. Projections are made in terms of constant U.S. dollars (2016), unadjusted for inflation. Growth is presented in terms of a compound average annual growth rate (CAGR). Sales values are measured at end consumer level; reasons are discussed in the report.


Geographic Breakdown
In this report, the geographic regions considered for market analysis include, and only include:
North China
• Beijing
• Hebei
• Shanxi
• Tianjin
• Inner Mongolia
East China
• Shanghai
• Shandong
• Zhejiang
• Jiangsu
• Fujian
• Anhui
South China
• Guangdong
• Guangxi
• Hainan
Middle China
• Hubei
• Henan
• Hunan
• Jiangxi
Northwest China
• Shaanxi
• Xinjiang
• Gansu
• Qinghai
• Ningxia

Southwest China
• Sichuan
• Chongqing
• Yunnan
• Guizhou
• Tibet
Northeast China
• Liaoning
• Heilongjiang
• Jilin

Country=China Industry=Cancer ParentIndustry=LifeSciences Date=201706 Topic=MarketShares Publisher=BCCResearch Price=5000